| Description | Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. |
| In vitro | Deslanoside increases forearm blood flow and cardiac index and decreased heart rate concomitant with a marked decrease in skeletal muscle sympathetic nerve activity [1]. Deslanoside is a metabolite of Lanatoside C [3]. |
| Synonyms | 洋地黄, 去乙酰西地兰, Desacetyllanatoside C, Deacetyllanatoside C |
| molecular weight | 943.08 |
| Molecular formula | C47H74O19 |
| CAS | 17598-65-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 95 mg/mL (100.73 mM), Sonication is recommended. |
| References | 1. Hauptman PJ, et al. Digitalis. Circulation. 1999 Mar 9;99(9):1265-70. 2. Wang L, et al. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. Sci Rep. 2017 Oct 23;7(1):13819. 4. Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. Forensic Sci Int. 1990 Apr;45(3):231-8. |